Home
Debiopharm

Debiopharm Market Share Analysis for June 2026

Everything we do is for the benefit of patients and their quality of life. Discover our open positions & join us to help make their lives better.

Health > Biotechnology and Pharmaceuticals

Domaindebiopharm.com

Year Founded1979

Employees201 - 500

Annual Revenue$100M - $200M

Debiopharm

Debiopharm (including company regionals)

debiopharm.com

See more website traffic and engagement information

Debiopharm Revenue up to June 2026 is 100M - 200M

revenue generated by Debiopharm top domains

Debiopharm top domains revenue over 3 years

Revenue for Debiopharm top domains

debiopharm.com100M - 200M

See more with Sales Intelligence

Total visits to Debiopharm's top domains

Understand Debiopharm market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

debiopharm.com21.2K

See more with Sales Intelligence

Avg. visit duration in Debiopharm's top domains

Analyze Debiopharm engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

debiopharm.com00:00:24

See more with Sales Intelligence

Avg. pageviews on Debiopharm's top domains

See how Debiopharm keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

debiopharm.com1.93

See more with Sales Intelligence

Debiopharm top competitors by domain

Top similar sites in June 2026, ranked by their affinity

iktos.aiCompany NameIktosEmployees51 - 200HQUnited States, Massachusetts, BostonAnnual revenue$2M - $5MTotal visits6.9KScience and Education > Chemistry

Top technologies used by Debiopharm

These are the website technologies, by industry, used by Debiopharm top domains

Widget (5)

reCAPTCHA

Advertising (4)

Google Adsense

Payment & Currencies (3)

PayPal

Content Management System (2)

WordPress

More Technologies

14

See all

News & Signals from Debiopharm

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsDebiopharm Group is developing multiple PAb001-ADC candidates on Jun 25th '26.Under the research collaboration, Debiopharm will design and produce multiple PAb001-ADC candidates using its MultiLINK(TM) platform, which integrates cytotoxic payloads, linkers connecting antibodies and payloads, and conjugation technologies.